CACNA1D and hyperaldosteronism: Given this key role of Cav1.3‐channels in hyperaldosteronism, Cav1.3‐selective inhibitors may reduce aldosterone secretion and serve as specific antihypertensives in treatment–resistant hypertension associated with APAs or APCCs (Xie et al., 2016; Yang et al., 2020).